Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) has a beta value of 2.47 and has seen 2.53 million shares traded in the last trading session. The company, currently valued at $186.90M, closed the last trade at $4.45 per share which meant it lost -$0.08 on the day or -1.77% during that session. The ZYNE stock price is -102.25% off its 52-week high price of $9.00 and 29.21% above the 52-week low of $3.15. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.01 million shares traded. The 3-month trading volume is 1.60 million shares.
The consensus among analysts is that Zynerba Pharmaceuticals Inc. (ZYNE) is an Overweight stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 4 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.24.
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) trade information
Sporting -1.77% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/03/21 when the ZYNE stock price touched $4.45 or saw a rise of 2.41%. Year-to-date, Zynerba Pharmaceuticals Inc. shares have moved 34.85%, while the 5-day performance has seen it change 7.23%. Over the past 30 days, the shares of Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) have changed -1.77%. Short interest in the company has seen 2.33 million shares shorted with days to cover at 1.3.
Wall Street analysts have a consensus price target for the stock at $7.17, which means that the shares’ value could jump 37.94% from current levels. The projected low price target is $4.50 while the price target rests at a high of $9.00. In that case, then, we find that the current price level is -102.25% off the targeted high while a plunge would see the stock gain -1.12% from current levels.
Zynerba Pharmaceuticals Inc. (ZYNE) estimates and forecasts
Figures show that Zynerba Pharmaceuticals Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained 7.49% over the past 6 months, with this year growth rate of 43.68%, compared to 5.70% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 69.20% and 19.40% for the next quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 7.60% over the past 5 years.
Zynerba Pharmaceuticals Inc. is expected to release its next earnings report between August 09 and August 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)’s Major holders
Insiders own 2.60% of the company shares, while shares held by institutions stand at 32.24% with a share float percentage of 33.10%. Investors are also buoyed by the number of investors in a company, with Zynerba Pharmaceuticals Inc. having a total of 84 institutions that hold shares in the company. The top two institutional holders are ETF Managers Group, LLC with over 1.99 million shares worth more than $9.24 million. As of Mar 30, 2021, ETF Managers Group, LLC held 4.82% of shares outstanding.
The other major institutional holder is AdvisorShares Investments, LLC, with the holding of over 1.54 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $7.15 million and represent 3.73% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ETF Managers Tr-EFTMG Alternative Harvest ETF and Global X Fds-The Global X Cannabis ETF. As of Mar 30, 2021, the former fund manager holds about 4.82% shares in the company for having 1.99 million shares of worth $9.24 million while later fund manager owns 1.3 million shares of worth $7.38 million as of May 30, 2021, which makes it owner of about 3.15% of company’s outstanding stock.